CV-14
/ Takeda, Cellivery
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 24, 2020
Cellivery Receives Life Preservation Results, New Drug for Incurable Diseases Treatment from Global Top 10 Pharmaceutical Companies [Google translation]
(Money Today Network (MTN))
- "At the proposal of a global top 10 pharmaceutical company, a cell/tissue-permeable prataxin recombinant protein formulation (CP-FXN) using Cellivery's 'in vivo delivery technology TSDT platform' was developed...'In the pharmacokinetic (PK) test...CP-FXN begins to be transmitted to the heart and brain tissue from 15 minutes after administration, and is transmitted to the highest in 1 hour'...'This disease animal model is a genetically transgenic animal that can simulate a human genetic disease'...It showed a survival rate 2.5 times higher than that of the control group even at the end of the experiment'....'We would like to have a strategic meeting of both development and co-development managers in one place on the important results and licensing directions obtained through this test.'"
New molecule • PK/PD data • Preclinical • Friedreich ataxia
1 to 1
Of
1
Go to page
1